Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2014

Hirai Fumihiko, Takenoyama Mitsuhiro, Taguchi Kenichi, Toyozawa Ryo, Inamasu Eiko, Toyokawa Gouji, Yoshida Tsukihisa, Shiraishi Yoshimasa, Takenaka Tomoyoshi, Yamaguchi Masafumi, Ushijima Chie, Seto Takashi, Takeo Sadanori, Ichinose Yukito

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Neoplasm Recurrence, Local

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 24722163
DOI: 10.1097/JTO.0000000000000097

Genes

EGFR
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.PMID 24722163Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.Semantic proximity Read ↗

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 casesSemantic proximity Read ↗

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.Semantic proximity Read ↗

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.Semantic proximity Read ↗

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.Semantic proximity Read ↗

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.Semantic proximity Read ↗

A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.Semantic proximity Read ↗

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome.Semantic proximity Read ↗

[Clinicopathological analysis of 6 cases of lung adenocarcinoma with concomitant EGFR mutation and ALK fusion].Semantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.